Histone deacetylase as a modulator of pdli expression and activity

Abstract

Disclosed herein is a method for modulating Program Death Receptor Ligand 1 (PDL1) in a cancer cell, comprising contacting the cell with a composition comprising a histone deacetylase (HDAC) inhibitor. Also disclosed is a method for treating a tumor in a subject, comprising administering to the subject a thereapeutically effective amount of a composition comprising a histone deacetylase (HDAC) inhibitor and a composition comprising a thereapeutically effective amount of a Program Death Receptor Ligand 1 (PDL1) inhibitor, a Programmed Death 1 receptor (PD1) inhibitor, or a combination thereof.

1 - 12 . (canceled) 
     
     
         13 . A method for treating a tumor in a subject, comprising administering to the subject a therapeutically effective amount of a histone deacetylase (HDAC) inhibitor and a therapeutically effective amount of a Programmed Death 1 receptor (PD1) inhibitor. 
     
     
         14 . The method of  claim 13 , wherein the HDAC inhibitor is a selective HDAC6 inhibitor. 
     
     
         15 . The method of  claim 14 , wherein the selective HDAC6 inhibitor is selected from the group consisting of ACY-1215, Tubacin, Tubastatin A, ST-3-06, ST-2-92, Nexturastat A, and Nexturastat B. 
     
     
         16 . The method of  claim 13 , wherein the tumor comprises a melanoma, renal cancer, or non-small cell lung cancer. 
     
     
         17 . The method of  claim 13 , wherein the PD1 inhibitor comprises an antibody that specifically binds PD1.